Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR‐TKIs in non‐small cell lung cancer

Compensatory activation of the signal transduction pathways is one of the major obstacles for the targeted therapy of non‐small cell lung cancer (NSCLC). Herein, we present the therapeutic strategy of combined targeted therapy against the MEK and phosphoinositide‐3 kinase (PI3K) pathways for acquire...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Sci
Autors principals: Sato, Hiroki, Yamamoto, Hiromasa, Sakaguchi, Masakiyo, Shien, Kazuhiko, Tomida, Shuta, Shien, Tadahiko, Ikeda, Hirokuni, Hatono, Minami, Torigoe, Hidejiro, Namba, Kei, Yoshioka, Takahiro, Kurihara, Eisuke, Ogoshi, Yusuke, Takahashi, Yuta, Soh, Junichi, Toyooka, Shinichi
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2018
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6172047/
https://ncbi.nlm.nih.gov/pubmed/30098066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13763
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars